BIOMARIN PHARMACEUTICAL INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.36 USD | +2.22% |
|
+3.09% | -11.33% |
| 10/06 | Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion | DJ |
| 10/06 | KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 | MT |
Presentation Operator MessageOperator (Operator)Welcome to the BioMarin Fourth Quarter and Ful...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
83.51
USD
Average target price
108.1
USD
Spread / Average Target
+29.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.33% | 1.59TCr | |
| +0.75% | 9.24TCr | |
| -3.16% | 3.79TCr | |
| -12.05% | 3.37TCr | |
| +73.89% | 2.8TCr | |
| -0.59% | 1.4TCr | |
| -11.18% | 1.17TCr | |
| +171.57% | 1.02TCr | |
| -50.45% | 1TCr | |
| +1.35% | 871.03Cr |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc., Q4 2018 Earnings Call, Feb 21, 2019
